Skip to content

Effectiveness of Online Systematic Brief Psychodynamic Psychotherapy for Neurotic Disorders: Randomized Controlled Trial

The Effectiveness of Online Systematic Brief Psychodynamic Psychotherapy Via HIPAA Complaint Web Conferencing on Adults With Neurotic Disorders: a Randomized Controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02257996
Enrollment
32
Registered
2014-10-07
Start date
2015-08-31
Completion date
2017-10-31
Last updated
2015-01-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neurotic Disorders

Keywords

Psychoanalytic Psychotherapy, Telepsychology, Online Therapy, Web conferencing, RCT, HIPAA

Brief summary

Objective: To evaluate the effectiveness of online systematic brief psychodynamic psychotherapy (SBPP) via HIPAA compliant web conferencing on adults with neurotic disorders. Design: Randomized controlled trial. Single blind. Setting: Internet users in the community, in São Paulo, Brazil. Participants: Thirty-two adults will be randomly allocated to a group will receive online systematic brief psychodynamic psychotherapy (n=16), or a waiting list group (n=16). Method: Systematic adaptative diagnosis system will be applied in both groups at pre-treatment and post-treatment (or post-waiting list). Assessment will be a comparison of the adaptative diagnosis evolution between groups. Primary Outcomes: The subjects treated with online brief systematic psychodynamic psychotherapy will present an increase in their adaptative efficacy measured by systematic adaptative diagnosis scale (SADS) in comparison to the waiting list group, when contrasting their initial and final adaptative diagnostics.

Interventions

BEHAVIORALOnline Systematic Brief Psychodynamic Psychotherapy

Systematic Adaptative Diagnosis System will be applied in both groups at two different times: pre-treatment and post-treatment

Sponsors

University of Sao Paulo
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
22 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Residents in Sao Paulo city, * Graduation complete or in course, * Fluent Portuguese, * Basic skills on english language, * If in psychiatric treatment, must be under treatment with stable dosage of psychiatric medication for at least 6 months, * Participants with diagnosis of neurotic disorders (F03.650), * Motivation for the therapeutic process, * Availability for 4 months of psychotherapy, * A personal computer (with an IP address), a web camera, a microphone, access to a 1 Mbps internet connection and specific computer configuration to access the Secure Psychotherapy Virtual Environment, * Basic knowledge of elementary internet tools, * A justified reason that impedes a in person psychotherapy, such as the ones below: * Lack of financial resources, * Frequent change of address due to work reasons, * Mobility restrictions related to accidents, illnesses or physical deficiencies, * Inability to arrive for psychotherapy appointments due to urban chaos.

Exclusion criteria

Participants that present: * a schizophrenia diagnostic or any other severe mental illness, * drug and alcohol dependence that are in abstinence from substance abuse, * untreated diagnosis of illnesses that may cause emotional imbalance, such as thyroid malfunction, * Participants that are undergoing a therapeutic process during the time of the research, * Individuals with both suicidal ideation and clear intent and need emergency treatment, * Participants do not possess the characteristics needed to be included in the sample or are bearers of deficiencies that may compromise the treatment mediated by a computer.

Design outcomes

Primary

MeasureTime frameDescription
Change in Systematic Adaptive Diagnosis Scale (SADS)Each participant will be followed, an expected average of 3 months.Participants of interventional group will be followed for the duration of therapeutic process, an expected average of 3 months. Participants of control group will be followed after waiting-list period, an expected average of 3 months.

Countries

Brazil

Contacts

Primary ContactClaudia CA Siqueira, MSc
claudiacatao@usp.br+5511985885778
Backup ContactMarcelo N Russo
mrusso@casadosinsights.com.br+5511992029060

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026